Physician

Zeeshan Ali Jawa, MD

According to 2025 Medicare claims, Zeeshan Jawa, MD (NPI: 1891055612) practices medical oncology in the Des Moines-West Des Moines, IA market, with the plurality of this provider's patient population coming from Polk, IA. This provider's primary affiliated billing organization is STATE UNIVERSITY OF IOWA (NPI: 1477554814; TIN: 426004813) and primary practice location at 50263-1299. Jawa is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Jawa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 628 traditional Medicare patients, billed 23,243 HCPCS/CPT codes, and received $414,078 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,395 prescription claims across 345 beneficiaries totaling $3,913,459 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 155 claims. Open Payments data shows 25 records totaling $22,118. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $2,204 to $3,913,459. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	85	89	$12,472
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	131	12,126	$235,154
2019	380	28,895	$608,904
2020	554	48,686	$792,096
2021	633	24,404	$506,588
2022	613	20,375	$402,702
2023	574	23,109	$447,844
2024	628	23,243	$414,078

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	25	$2,204
2016	N/R	14	$448
2017	N/R	N/R	N/R
2018	53	176	$136,251
2019	156	1,125	$729,780
2020	218	1,809	$1,251,063
2021	238	1,769	$1,399,684
2022	293	2,009	$2,023,784
2023	313	2,023	$2,149,893
2024	345	2,395	$3,913,459

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	11	$1,562
2020	N/R	30	$1,704
2021	N/R	77	$3,874
2022	39	155	$6,427
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	387	867	$89
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	347	606	$12
80053	Blood test, comprehensive group of blood chemicals	290	1,144	$10
36415	Insertion of needle into vein for collection of blood sample	276	970	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	292	1,262	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	42	1,176	$1,014,845
Nubeqa	Darolutamide	35	1,050	$473,982
Verzenio	Abemaciclib	28	784	$422,334
Xtandi	Enzalutamide	29	870	$405,542
Kisqali	Ribociclib Succinate	21	601	$313,334

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$493	Aveo Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$21,625	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Zeeshan Ali Jawa, MD?

Tedicare shows public-source Medicare data for Zeeshan Ali Jawa, MD (NPI 1891055612), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Zeeshan Ali Jawa, MD have ACO affiliation data?

Zeeshan Ali Jawa, MD is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Zeeshan Ali Jawa, MD?

Zeeshan Ali Jawa, MD is linked to STATE UNIVERSITY OF IOWA (billing NPI 1477554814) in the available physician profile data.

Does Zeeshan Ali Jawa, MD have Open Payments data?

Zeeshan Ali Jawa, MD has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.